Compare Abbott Laboratories (ABT) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Main Street Capital Corporation — how do they compare? Abbott Laboratories trades at $95.17 (market cap $166.94B), while Main Street Capital Corporation trades at $51.31 (market cap $4.87B). The key difference: Abbott Laboratories is far larger — about 34.3× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.36%). Which is the better fit depends on your goals.
| ABT | MAIN | |
|---|---|---|
Market Cap | $166.94B | $4.87B |
Sector | Health | Financials |
52-Week High | $136.62 | $67.54 |
52-Week Low | $82.57 | $49.63 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 8.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Main Street Capital (MAIN) trades at $52.41, up 0.87% on the day, with a bullish technical signal and strong support near $52. The company reported a net income margin of 81.08% for 2025, though revenue declined slightly to $592 million. Recent corporate actions include a credit facility amendment extending maturity to 2031 and consistent dividend payments, highlighting its income-focused appeal.
Outlook remains mixed; the stock offers a high yield and stable dividends, but earnings misses and a high RSI suggest near-term caution. Analyst consensus is a Hold with a $57.75 price target, indicating modest upside potential amid execution risks and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
